Associated with its better antitumor activity, TRIMELVax induced a higher tumor infiltration of CD3+, CD4+ and CD8+ cells than anti-PD-1 monotherapy, while TRIMELVax/anti-PD-1 combination generated higher tumor infiltration of CD4+ cells than each treatment alone (figure 6A). The gene discussed is PDCD1; the disease is neoplasm.